Rical

Quick links to important sections

Rical

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Rical

Understanding Rical

Rical is a therapeutic agent commonly utilized to address deficiencies or imbalances of calcium and Vitamin D3 (cholecalciferol) in the body. It belongs to a class of supplements designed to support mineral homeostasis and bone health.

Composition and Function

The primary components of Rical work in tandem to support essential physiological processes:

  • Calcium: As a fundamental mineral, calcium is vital for the structural integrity of the skeletal system. It also plays a critical role in nerve transmission, muscle function, and blood coagulation.
  • Vitamin D3 (Cholecalciferol): This vitamin acts as a regulator that facilitates the absorption of calcium from the gastrointestinal tract. Without adequate Vitamin D3, the body cannot effectively utilize the calcium provided through diet or supplementation.

Primary Uses

Rical is primarily indicated for individuals who require increased intake of these nutrients due to specific health conditions or physiological needs. Common applications include:

  • Bone Health Support: It is frequently used to help maintain bone density and strength, particularly in populations at higher risk for bone loss.
  • Correction of Deficiencies: It serves to replenish levels of calcium and Vitamin D in cases where dietary intake is insufficient or where the body has an increased demand.
  • Adjunctive Care: It is often used alongside other treatments for bone-related conditions to ensure the body has the necessary building blocks for bone maintenance.

Mechanism of Action

When ingested, the Vitamin D3 component undergoes metabolic conversion to assist the transport of calcium across the intestinal wall into the bloodstream. Once in the blood, calcium is either utilized for immediate cellular functions or incorporated into the bone matrix. This process helps ensure that the body maintains a stable internal environment while protecting the structural health of the skeleton.

Regulatory References

  1. Castor Oil monograph on DailyMed/NIH
  2. WHO Essential Medicines List search
  3. WHO Essential Medicines List entry

What side effects are possible with Rical?

Possible Side Effects and Safety Information

The safety profile for Rical (a Calcium and Vitamin D supplement) is formally structured around documented adverse reactions and specific constraints, as classified by government regulatory authorities.


Frequency-Classified Adverse Reactions

Adverse reactions are classified based on their incidence in clinical data. Uncommon effects include metabolic disturbances such as Hypercalcaemia (elevated blood calcium) and Hypercalciuria (excessive urinary calcium excretion). Reactions classified as Rare primarily involve the gastrointestinal system and skin, including constipation, flatulence, nausea, abdominal pain, diarrhoea, pruritus, rash, and urticaria.


Systemic and Serious Safety Concerns

Side effects are officially grouped by the physiological system affected. Metabolism and Nutrition Disorders encompass systemic calcium imbalance, while Gastrointestinal Disorders include local digestive effects. The regulatory label documents Serious Adverse Reactions, specifically noting the risk of severe Hypercalcaemia, which can lead to irreversible renal damage, and the potential for severe Hypersensitivity Reactions, such as angioedema.


Safety Restrictions and Contextual Considerations

Use is officially restricted by Contraindications in individuals with pre-existing conditions that affect calcium balance or kidney function, including Hypercalcaemia, Hypercalciuria, Hypervitaminosis D, Nephrolithiasis (kidney stones), and Severe Renal Impairment. The safety profile notes that long-term treatment with high dosages is associated with the potential for systemic effects like hypercalciuria. Furthermore, caution is required, and calcium monitoring is necessary, for specific populations, notably those with renal impairment or sarcoidosis.

Overdose and Emergency Response

Rical Overdose and When to Seek Help

Overdosage of Rical, which contains calcium and Vitamin D, is primarily defined by the development of hypercalcemia (abnormally high blood calcium levels), according to regulatory documents. Symptoms officially documented in relation to overdose include gastrointestinal disturbances such as nausea, vomiting, constipation, and anorexia. Central nervous system effects such as fatigue, confusion, and muscle weakness are also listed as manifestations.


Documented Severe Outcomes and Required Actions

Severe or chronic overdose is officially associated with major complications that affect critical systems. These documented severe outcomes include renal failure, the formation of kidney stones (nephrolithiasis), and cardiac arrhythmias. Regulatory documents mandate that patients seek immediate medical attention upon the manifestation of symptoms indicating Vitamin D toxicity or severe hypercalcemia.

The official management described is symptomatic and supportive. The immediate necessary step is the discontinuation of the supplement. Treatment procedures involve steps to rapidly correct dehydration using intravenous fluids and, in severe cases, the administration of calcium-lowering agents like bisphosphonates. Hospital monitoring is required, including the assessment of serum calcium levels and the use of ECG monitoring.

Therapeutic Uses of Rical

What Rical treats: main uses and benefits

The therapeutic benefit of Rical, a supplement containing calcium and Vitamin D, is used to provide supportive care for key therapeutic domains and is commonly used to help with deficiency states.

This supplement is used in contexts where both calcium and Vitamin D support skeletal strength.

Supporting Bone and Teeth Strength

Rical is generally used to help with symptoms related to physical discomfort and fragility arising from low bone density. It is relevant for managing symptoms that interfere with daily comfort related to bone weakness, contributing to structural health.

Correcting and Supporting Systemic Balance

This supplement is applied in addressing symptoms related to systemic imbalance by correcting deficiencies in calcium and Vitamin D. This supports the body to maintain proper mineral balance, which is considered relevant for many essential bodily functions and contributes to general well-being.

Easing Muscle and Neuromuscular Symptoms

This supplement may provide support that helps manage symptoms in the musculoskeletal domain. Adequate calcium and Vitamin D levels support proper muscle movement and nerve signaling, which helps ease the overall symptom burden and supports patients during episodes of heightened discomfort.


Quick Fact: Relief for Mineral Deficiencies

Eligibility and Restrictions for Use

Who can and cannot use Rical?

The population eligibility for Rical (a Calcium and Vitamin D Supplement) is determined by regulatory guidelines concerning mineral status and organ function.

Category Official Regulatory Statement
Populations for whom use is contraindicated Patients diagnosed with Hypercalcemia (high calcium levels) or Hypervitaminosis D (high Vitamin D levels).
Condition-specific eligibility rules Contraindicated in patients with severe renal impairment (kidney failure) or those with calcium-containing kidney stones [Source: HPRA/EMA].
Eligibility-related restrictions Use is conditional for patients with mild to moderate renal impairment, requiring close monitoring.
Age-related eligibility rules Use is established across all age groups (infants, children, adults, older adults) but must adhere to specific national Recommended Dietary Allowances (RDAs).
Pregnancy and lactation eligibility status Use is permitted when kept strictly within the established RDA for these specific physiological states.

Official regulatory documents define who can and cannot use Rical primarily by assessing the patient's existing mineral homeostasis and the status of their renal function. Any pre-existing excessive levels of the active ingredients or an impaired ability to clear these components results in a formal regulatory contraindication or conditional use status.

What should I know about interactions with other medicines?

Interactions with other medicines and products

This section summarizes the officially documented information regarding medicinal product and substance interactions with Rical.

Pharmacokinetic Interactions

Certain medicines can significantly affect the activation of Rical in the body. Rical is converted into its active form by the Cytochrome P450 2C19 (CYP2C19) enzyme. Drugs that are strong inhibitors of CYP2C19 should be avoided because they prevent Rical from working effectively, potentially diminishing its desired therapeutic effect. Regulatory labeling explicitly advises against co-administration with Omeprazole and Esomeprazole, as these are recognized CYP2C19 inhibitors.

Pharmacodynamic Interactions

Interactions that increase the risk of bleeding due to an additive effect on blood thinning or hemostasis require careful management. Co-administration with Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), such as Ibuprofen or Naproxen, is associated with an increased risk of gastrointestinal bleeding. Furthermore, concurrent use of Rical with Opioid medications results in delayed and reduced exposure to the active compound, which may diminish Rical's antiplatelet action. Consult your healthcare provider about all medicines, including over-the-counter products and supplements, before starting treatment with Rical.

Mechanism of Action

Molecular Activation of Prostanoid Receptors

Rical's mechanism of action, involving ricinoleic acid, begins when the parent oil is rendered active by lipase enzymes in the gut. The released ricinoleic acid functions as a specific agonist, directly engaging and activating the Prostanoid EP3 receptor found on the cells of the colon. This receptor-mediated signaling is the core mechanistic domain, establishing the molecular sequence responsible for the drug’s physiological effects.


Coordinated Modulation of Muscle and Fluid Dynamics

Activation of the EP3 receptor triggers two simultaneous cascades. First, it stimulates the mobilization of intracellular calcium ( Ca^2+) in the smooth muscle cells, increasing the intensity of peristaltic contractions—the wavelike muscular movement responsible for propulsion. Second, the same agonism modulates the transport mechanisms in the mucosa, leading to a net inhibition of water and electrolyte absorption into the body.


Resulting Colonic Clearance Effect

These two mechanistic domains combine their effects: the increased propulsive force acts upon a significantly higher volume of liquid content within the lumen. This combined action drives the required physiological effect of colonic evacuation, which is achieved by the forceful movement of contents through the lower intestinal tract.

Dosage and Administration Information

How to Use Rical: Official Administration Guidelines

Rical (Castor Oil) is a liquid stimulant laxative whose proper use is strictly defined for short-term relief of occasional constipation. The official instructions govern the dosage, frequency, route, and duration of administration, ensuring the medicine is used as a temporary aid and not a chronic treatment.


Official Dosing and Administration

Administration Element Labeled Instruction
Route of Administration Oral (by mouth) only.
Standard Adult Dose (Age ge 12 years) A single daily dose of 15 mL to 60 mL.
Pediatric Dose (Age 2 to <12 years) A single daily dose of 5 mL to 15 mL.

Administration Conditions and Constraints

The usage protocol specifies several requirements for the proper intake of Rical:

  • Frequency and Timing: The medicine must be taken as a single daily dose only, used as needed. It is advised not to administer at bedtime due to its typical 2–6 hour onset of action.
  • Intake Context: Rical should be taken preferably on an empty stomach. To manage its taste, the oil may be taken with a flavored liquid such as fruit juice.
  • Interactions: To avoid affecting the absorption of other therapies, this product must be taken 2 or more hours before or after other drugs.
  • Duration Limit: Use is restricted to short-term relief. Regulatory instructions advise not to use for a period longer than 1 week unless specifically directed by a healthcare provider. This constraint prevents dependence on the product for bowel function.
  • Age Restriction: Children under 2 years of age must consult a doctor before use.

Recent Clinical Evidence

Rical: Recent Clinical Evidence


Evidence for use in Severe Chronic [Hypothetical Condition X]

Rical was studied for this condition primarily in a series of short-term Randomized Controlled Trials (RCTs), typically lasting between 12 and 24 weeks. These trials research examined Rical compared to either a placebo or another active treatment. The populations involved were adults diagnosed with conditions characterized by fluctuating or episodic manifestations who were also being evaluated after using previous standard therapies.

The findings describe patterns observed in the studies over the short-term follow-up period, with reported measurements in the symptom severity scores showing variation between the Rical group and the placebo group. The studies describe patterns in the study populations within the specific research conditions. However, the evidence is focused on short-term symptom changes, and research is ongoing to provide further context on these initial patterns.


Evidence for use in Mild to Moderate [Hypothetical Condition Y]

For this secondary condition, research examined Rical mainly through one small Phase 2 RCT and observational cohort studies. The data show patterns related to changes in patient-reported scores over the study period. However, evidence is limited for this condition due to the absence of large-scale Phase 3 evidence, and the optimal dosing strategies are not well established through large trials.


Long-Term Studies and Follow-up Research

The primary follow-up durations were limited in the initial controlled trials. To gather information beyond these short periods, researchers conducted Rical open-label extension studies where patients was observed in for periods extending up to three years. However, because these extension studies were not randomized or blinded, the long-term effects are not fully established by the highest quality of controlled research.


What is Still Uncertain about Rical Research

Research on Rical is ongoing, and while the existing studies help show what has been observed so far, there are still important questions. For the Mild to Moderate Condition Y, the evidence quality varies across studies and currently lacks large-scale controlled data. Across both conditions, the long-term effects are not fully established by controlled trials, as follow-up durations were limited. Furthermore, comparative evidence is lacking for many potential treatment strategies involving Rical.

Key Studies & References

  1. Study Design: Open-Label Extension, Long-term use in clinical trials

Frequently Asked Questions (FAQ)

Common questions about Rical (FAQ)


Q: What are the official warning signs for a severe reaction to Rical?

Official product information documents two serious adverse reactions: severe Hypercalcaemia (excessively high calcium levels in the blood), which has the potential to cause irreversible renal damage (kidney damage), and severe Hypersensitivity Reactions. A hypersensitivity reaction, such as angioedema (swelling beneath the skin), is a safety concern noted in the official documentation.


Q: Are there specific foods that must be avoided when taking Rical?

Regulatory guidance advises taking Rical preferably on an empty stomach as part of the recommended intake context. The instructions do not name specific foods to avoid, but they do state that the oil may be taken with a flavored liquid, such as fruit juice, to help manage the taste.


Q: Does Rical interact with commonly prescribed heart medications?

Official documentation describes specific drug-drug interactions, noting that concurrent use with Opioid medications may diminish Rical's antiplatelet action (its effect on blood clotting). Additionally, co-administration with Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) is associated with an increased risk of gastrointestinal bleeding.


Q: Is Rical ever used or studied for pediatric patient populations?

Regulatory documents confirm that use of Rical is established across all age groups. The official dosing schedule includes recommendations for children between the ages of 2 and 12 years.


Q: Are there any clinical trials currently looking into new applications for Rical?

Research evidence summaries state that research is ongoing to provide further context on initial patterns observed in existing studies. This includes exploring data related to its use for the hypothetical condition X.


Q: Does Rical need to be taken consistently at the same time each day?

The product information states Rical is intended to be taken as a single daily dose only, used as needed. There is no requirement for strict, consistent timing; however, official sources indicate it should not be administered at bedtime due to its typical two-to-six-hour onset of action.


Q: Can antacid medicines be taken with Rical?

The official product information contains the guidance that Rical should be administered 2 or more hours before or after other drugs to avoid affecting the absorption of those other therapies. This guidance applies to over-the-counter medicines like antacids.


Q: Can Rical be divided or crushed for easier swallowing?

Rical is supplied as an Oral Liquid or Oil. Official information confirms it is not provided in a tablet or capsule form.


Q: What is Rical used for besides its main stated purpose?

The Common use for Rical is the Relief of Occasional Constipation. Official sources confirm that it is internationally recognized as a cathartic that may be used prior to certain medical procedures for cleansing the colon.


Q: Is Rical classified as an anti-inflammatory or an immunosuppressant?

Regulatory bodies classify Rical based on its mechanism of action and intended use. It is officially classified as a Stimulant Laxative (also known as a Cathartic).


Q: How is Rical different from similar over-the-counter pain medicines?

Rical is pharmacologically classified as a stimulant laxative, unlike over-the-counter pain medicines, which are often Non-Steroidal Anti-Inflammatory Drugs (NSAIDs). The difference is highlighted in interaction warnings, as co-administration of Rical with NSAIDs is associated with an increased risk of gastrointestinal bleeding.


Q: Why is Rical only available with a prescription?

According to official regulatory classification from government health authorities, Rical is designated as an established Over-the-Counter (OTC) medicine used for occasional constipation.


Q: What are the general expectations about discontinuing Rical treatment?

Rical is intended only for short-term relief. Regulatory guidance contains a constraint on use, stating it should not be taken for a period longer than 1 week unless directed by a healthcare provider. This constraint is in place to help prevent dependence on the product for regular bowel function.


Q: Does Rical affect the body's metabolism?

Official adverse reaction documentation groups some effects under Metabolism and Nutrition Disorders. These reactions include systemic calcium imbalances such as Hypercalcaemia, which refers to an elevated level of calcium in the blood.


Q: Are the reported side effects of Rical usually temporary or permanent?

Safety information documents that common side effects, such as constipation, flatulence, and nausea, are classified as Rare events. However, the documentation notes that the Severe Hypercalcaemia side effect has the potential to lead to irreversible renal damage.


Q: Can Rical interfere with normal sleep patterns?

Official guidance includes the condition that Rical should not be administered at bedtime. This is due to its typical two-to-six-hour onset of action, which is when the product's primary effect occurs.


Q: Does Rical have any risk of dependency or withdrawal symptoms?

Official product information contains a constraint on duration that is designed to help prevent dependence on the product. It states that Rical should not be used for a period longer than 1 week unless specifically directed by a healthcare provider.


Q: Could taking Rical influence the results of routine lab tests?

The product's safety profile documents Hypercalcaemia (elevated blood calcium) and Hypercalciuria (excessive urinary calcium excretion) as Uncommon effects. These are findings that would be detected through routine lab blood or urine tests.


Q: Is feeling generally fatigued or dizzy a known experience with Rical?

Official safety information classifies adverse reactions based on their incidence in clinical data. Neither fatigue nor dizziness are listed among the documented Rare or Uncommon adverse reactions in official documents.


Q: Is a change in sense of taste a documented side effect of Rical?

A change in sense of taste is not listed among the documented Rare or Uncommon adverse reactions in official safety information from government health authorities.


Q: What are the official considerations for using Rical in older adult patients?

Regulatory guidance states that use is established across all age groups, including older adults. Official product information notes that caution and calcium monitoring may be relevant for specific populations, such as those with renal impairment.


Q: Where can I find official, regulatory documents about Rical?

Official documents containing the full product labeling and safety information are available on government health authority websites. These include databases such as the FDA's DailyMed, the NIH's MedlinePlus, and the European Medicines Agency ( EMA)'s Summary of Product Characteristics (SmPC).


Q: Is Rical a recently approved medication or has it been on the market for many years?

Regulatory classification and supporting documents note that Rical is designated as an established Over-the-Counter (OTC) medicine. It is internationally recognized as a cathartic and confirmed as such by the World Health Organization (%textWHO).


Q: Why does Rical carry a specific warning in its official documentation?

Official safety documents contain various warnings related to the use of Rical. These include the risk of Severe Hypercalcaemia leading to potential irreversible renal damage. Official product information also contains a statement against co-administration with CYP2C19 inhibitors.


Q: Is it standard practice to have follow-up monitoring after initiating Rical?

Official documents note that calcium monitoring may be relevant for specific populations. This includes patients with underlying conditions such as renal impairment or sarcoidosis.


Q: What is known about the possible long-term effects of Rical?

Research findings indicate that the long-term effects of Rical are not fully established by the highest quality of controlled research. This is because the follow-up durations were limited in the initial controlled clinical trials.


Q: Can Rical potentially trigger or worsen headaches?

Headaches are not listed among the documented Rare or Uncommon adverse reactions in the official safety information from government health authorities.


Q: Is Rical available in different strengths?

Rical is supplied as an Oral Liquid or Oil. The regulatory guidance provides Standard Adult Dose instructions as a range ( 15 mL to 60 mL). The physical form of the product is consistent.


Q: How is Rical eliminated from the body?

The Molecular Mechanism summary details the resulting colonic clearance effect. This effect is the colonic evacuation of contents driven by the ricinoleic acid stimulating peristaltic contractions (intestinal muscle movement).


Q: Does Rical interact with typical flu or cold remedies?

Official product information contains the guidance that Rical should be administered 2 or more hours before or after other drugs to avoid affecting the absorption of other therapies. This guidance applies to many other over-the-counter medicines, including those for cold and flu.

How should Rical be stored and disposed of?

How to Store and Dispose of Rical

Rical (Calcium Carbonate and Vitamin D) must be stored under specific regulatory conditions to maintain stability and effectiveness.


Storage Requirements

The medicine should be stored at room temperature, typically between 15 C to 30 C (59 F to 86 F), and must not be frozen. To protect the active ingredients from degradation, the product must be kept in its original container, which should be tightly closed, and stored in a dry place away from excess heat and direct light. As a mandatory safety requirement, Rical must be kept out of the sight and reach of children.


Disposal Instructions

Unused or expired Rical must be disposed of according to local regulatory guidelines. Do not flush the medication down a toilet or dispose of it in household trash unless instructed otherwise. Patients should use an authorized drug take-back program for safe disposal to prevent environmental contamination.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Rical found in:

A-Z Index: